Neurocrine Bio. (NBIX) PT Raised to $32 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
Neurocrine Bio (NBIX) Price Target Raised at Deutsche Bank Following Positive Elagolix Phase 3
January 8, 2015 3:36 PM ESTDeutsche Bank Buy Neurocrine Bio. (NASDAQ: NBIX) price target of $35.00 (from $25.00). Yesterday it an AbbVie (NYSE: ABBV) announced positive top-line results from the first of two ongoing Phase 3 clinical trials designed to evaluate the efficacy and safety of elagolix in... More
AbbVie (ABBV) Issues Positive Top-Line Data from Two Elagolix Combo Phase 3s (NBIX)
January 8, 2015 8:02 AM ESTAbbVie (NYSE: ABBV) in cooperation with Neurocrine Biosciences, Inc. (Nsdaq: NBIX), announced positive top-line results from the first of two ongoing Phase 3 clinical trials, designed to evaluate the efficacy and safety of elagolix in premenopausal women with... More
